| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/LIV.12637 |
| P698 | PubMed publication ID | 25040497 |
| P50 | author | Guido Gerken | Q17575163 |
| Andreas Bockisch | Q27342068 | ||
| P2093 | author name string | Alexander Dechêne | |
| Stefan Mueller | |||
| Joerg F Schlaak | |||
| Judith Ertle | |||
| Thomas Lauenstein | |||
| Mohamed K Shaker | |||
| Amr El Fouly | |||
| Eman Barakat | |||
| Ahmed El Dorry | |||
| Heba Abdella | |||
| P2860 | cites work | A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation | Q46540011 |
| Epidemiology of hepatocellular carcinoma in Hispanics in the United States | Q46792059 | ||
| SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer | Q47995666 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. | Q51192472 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Is radioembolization ready for the barcelona clinic liver cancer staging system? | Q51642139 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization | Q28111719 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
| Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients | Q30892049 | ||
| Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors | Q33376925 | ||
| Chemoembolization for hepatocellular carcinoma | Q34552214 | ||
| Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort | Q34556277 | ||
| Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. | Q34635723 | ||
| Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation | Q34982068 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma | Q35085486 | ||
| Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. | Q36573194 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation | Q37236887 | ||
| Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
| Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer | Q43885252 | ||
| Prospective validation of the Barcelona Clinic Liver Cancer staging system | Q44369884 | ||
| Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival | Q44451332 | ||
| P433 | issue | 2 | |
| P921 | main subject | yttrium | Q941 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | 627-635 | |
| P577 | publication date | 2014-08-02 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? | |
| P478 | volume | 35 |
| Q91949462 | Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q38786064 | Current role of selective internal radiation with yttrium-90 in liver tumors |
| Q40443863 | Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma |
| Q26799046 | Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors |
| Q35626761 | Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives |
| Q50026313 | Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma |
| Q47384456 | Institutional Decision to Adopt Y90 as Primary Treatment for HCC Informed by a 1,000-patient 15-year Experience. |
| Q35626764 | Intermediate hepatocellular carcinoma: How to choose the best treatment modality? |
| Q38782906 | Intermediate hepatocellular carcinoma: the role of transarterial therapy. |
| Q38792625 | Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation |
| Q92081825 | Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile |
| Q38979742 | Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma |
| Q64101477 | Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma |
| Q39241689 | Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment. |
| Q30252143 | Management strategies for hepatocellular carcinoma: old certainties and new realities. |
| Q53216812 | Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. |
| Q36009432 | Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. |
| Q47724444 | Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study |
| Q26741882 | The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review |
| Q37687824 | Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses |
| Q26753089 | Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma |
| Q40099351 | Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. |
| Q38820543 | Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality |
| Q26799469 | Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients |
| Q28081783 | Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives |
| Q26738273 | Transarterial radioembolization for hepatocellular carcinoma: a review |
| Q38883028 | Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis |
| Q89778037 | Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review |
| Q37474833 | Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review |
| Q26743603 | Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review |
| Q24186130 | Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma |
| Q35631304 | Yttrium-90 microsphere radioembolization for hepatocellular carcinoma |
| Q50218004 | Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. |
| Q58804965 | Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis |
Search more.